JP2003520232A5 - - Google Patents

Download PDF

Info

Publication number
JP2003520232A5
JP2003520232A5 JP2001552892A JP2001552892A JP2003520232A5 JP 2003520232 A5 JP2003520232 A5 JP 2003520232A5 JP 2001552892 A JP2001552892 A JP 2001552892A JP 2001552892 A JP2001552892 A JP 2001552892A JP 2003520232 A5 JP2003520232 A5 JP 2003520232A5
Authority
JP
Japan
Prior art keywords
dosage
double
sufficient
formulation according
normal blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001552892A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003520232A (ja
JP4794794B2 (ja
Filing date
Publication date
Priority claimed from AUPQ5146A external-priority patent/AUPQ514600A0/en
Application filed filed Critical
Publication of JP2003520232A publication Critical patent/JP2003520232A/ja
Publication of JP2003520232A5 publication Critical patent/JP2003520232A5/ja
Application granted granted Critical
Publication of JP4794794B2 publication Critical patent/JP4794794B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2001552892A 2000-01-18 2001-01-18 脳、脊髄および神経損傷の治療 Expired - Fee Related JP4794794B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU5146 1986-03-21
AUPQ5146 2000-01-18
AUPQ5146A AUPQ514600A0 (en) 2000-01-18 2000-01-18 Brain injury treatment
PCT/AU2001/000046 WO2001052844A1 (en) 2000-01-18 2001-01-18 Brain, spinal and nerve injury treatment

Publications (3)

Publication Number Publication Date
JP2003520232A JP2003520232A (ja) 2003-07-02
JP2003520232A5 true JP2003520232A5 (US07794700-20100914-C00152.png) 2008-03-13
JP4794794B2 JP4794794B2 (ja) 2011-10-19

Family

ID=3819274

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001552892A Expired - Fee Related JP4794794B2 (ja) 2000-01-18 2001-01-18 脳、脊髄および神経損傷の治療

Country Status (21)

Country Link
US (5) US6841551B2 (US07794700-20100914-C00152.png)
EP (1) EP1261335B1 (US07794700-20100914-C00152.png)
JP (1) JP4794794B2 (US07794700-20100914-C00152.png)
KR (1) KR100780119B1 (US07794700-20100914-C00152.png)
CN (1) CN1261095C (US07794700-20100914-C00152.png)
AU (2) AUPQ514600A0 (US07794700-20100914-C00152.png)
BR (1) BR0107695A (US07794700-20100914-C00152.png)
CA (1) CA2397723C (US07794700-20100914-C00152.png)
CZ (1) CZ20022804A3 (US07794700-20100914-C00152.png)
DE (1) DE60139244D1 (US07794700-20100914-C00152.png)
HK (1) HK1054872A1 (US07794700-20100914-C00152.png)
HR (1) HRP20020593B1 (US07794700-20100914-C00152.png)
HU (1) HUP0301920A3 (US07794700-20100914-C00152.png)
IL (2) IL150548A0 (US07794700-20100914-C00152.png)
MX (1) MXPA02007004A (US07794700-20100914-C00152.png)
NO (1) NO329320B1 (US07794700-20100914-C00152.png)
NZ (2) NZ534278A (US07794700-20100914-C00152.png)
RU (1) RU2276996C2 (US07794700-20100914-C00152.png)
WO (1) WO2001052844A1 (US07794700-20100914-C00152.png)
YU (1) YU54702A (US07794700-20100914-C00152.png)
ZA (1) ZA200205715B (US07794700-20100914-C00152.png)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
MXPA05008097A (es) 2003-01-28 2006-02-08 Microbia Inc Metodos y composiciones para el tratamiento de desordenes gastrointestinales.
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
GB0410215D0 (en) * 2004-05-07 2004-06-09 Lescroart Pol Nerve damage
JP2008514612A (ja) * 2004-09-23 2008-05-08 ミシャロウ、アレクサンダー 対抗適応を誘発することにより神経伝達物質系を調節する方法
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
CN101128189A (zh) 2005-02-25 2008-02-20 弗·哈夫曼-拉罗切有限公司 药物物质分散性改善的片剂
WO2006110118A1 (fr) * 2005-04-15 2006-10-19 Victor Pavlovich Kutnyak Produit cytoprotecteur
US8185176B2 (en) 2005-04-26 2012-05-22 Novadaq Technologies, Inc. Method and apparatus for vasculature visualization with applications in neurosurgery and neurology
US20060239921A1 (en) * 2005-04-26 2006-10-26 Novadaq Technologies Inc. Real time vascular imaging during solid organ transplant
WO2007016790A1 (en) * 2005-08-10 2007-02-15 Novadaq Technologies, Inc. Intra-operative head & neck nerve mapping
US20070122344A1 (en) * 2005-09-02 2007-05-31 University Of Rochester Medical Center Office Of Technology Transfer Intraoperative determination of nerve location
US20070154448A1 (en) * 2005-11-22 2007-07-05 Ted Reid Methods and compositions using Substance P to promote wound healing
US8945623B2 (en) * 2006-05-03 2015-02-03 Warsaw Orthopedic, Inc. Compositions comprising biomembrane sealing agent for treatment of neuronal injury, and methods of use
US20080161744A1 (en) 2006-09-07 2008-07-03 University Of Rochester Medical Center Pre-And Intra-Operative Localization of Penile Sentinel Nodes
US20100086543A1 (en) * 2007-04-02 2010-04-08 Saint Louis University Compositions and methods for treating conditions associated with ceramide biosynthesis
US20080241121A1 (en) * 2007-04-02 2008-10-02 Daniela Salvemini Inhibitors of the ceramide metabolic pathway as adjuncts to opiates for pain
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2008278273A1 (en) * 2007-07-19 2009-01-22 Adelaide Research & Innovation Pty Ltd Method for reducing intracranial pressure
US8406860B2 (en) 2008-01-25 2013-03-26 Novadaq Technologies Inc. Method for evaluating blush in myocardial tissue
US10219742B2 (en) 2008-04-14 2019-03-05 Novadaq Technologies ULC Locating and analyzing perforator flaps for plastic and reconstructive surgery
US20090263507A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Biological markers and response to treatment for pain, inflammation, neuronal or vascular injury and methods of use
EP3372250B1 (en) 2008-05-02 2019-12-25 Novadaq Technologies ULC Methods for production and use of substance-loaded erythrocytes for observation and treatment of microvascular hemodynamics
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
AU2009334511C1 (en) 2008-12-31 2016-08-18 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US8852566B2 (en) * 2009-03-26 2014-10-07 Warsaw Orthopedic, Inc. Compositions and methods for preferential distribution of active agents to injury sites
US10492671B2 (en) 2009-05-08 2019-12-03 Novadaq Technologies ULC Near infra red fluorescence imaging for visualization of blood vessels during endoscopic harvest
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012074043A1 (ja) * 2010-12-03 2012-06-07 国立大学法人 岡山大学 外傷性神経障害治療剤
WO2012125020A1 (en) * 2011-03-14 2012-09-20 N.V. Nutricia Method for treating neurotrauma
US10278585B2 (en) 2012-06-21 2019-05-07 Novadaq Technologies ULC Quantification and analysis of angiography and perfusion
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
BR112015003527A2 (pt) 2012-08-21 2017-07-04 Ardelyx Inc compostos e métodos para inibição de antiporte mediado por nhe no tratamento de desordens associadas à retenção de fluido ou sobrecarga de sal e desordens do trato gastrointestinal
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
SI2983667T1 (sl) 2013-04-12 2019-09-30 Ardelyx, Inc. Spojine za vezavo NHE3 in metode za zaviranje transporta fosfata
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
EP3016658A4 (en) * 2013-07-02 2017-03-15 Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) Method for preventing and/or treating chronic traumatic encephalopathy-iv
MX2015017881A (es) * 2013-07-02 2016-09-14 Eustralis Pharmaceuticals Ltd (Trading As Pressura Neuro) Método para el tratamiento y/o prevención contra encefalopatía traumática crónica grado ii.
AU2014286925A1 (en) * 2013-07-02 2015-12-17 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Method for preventing and/or treating chronic traumatic encephalopathy-I
EP3016659A4 (en) * 2013-07-02 2017-03-15 Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) Method for preventing and/or treating chronic traumatic encephalopathy-iii
WO2016049756A1 (en) 2014-09-29 2016-04-07 Novadaq Technologies Inc. Imaging a target fluorophore in a biological material in the presence of autofluorescence
KR101955134B1 (ko) 2014-10-09 2019-03-06 노바다크 테크놀러지즈 유엘씨 형광-조정 광전용적맥파 측정기를 사용한 조직 내의 절대적인 혈류의 정량화
MX2019008171A (es) 2017-01-09 2020-02-05 Ardelyx Inc Inhibidores del antiporte mediado por nhe.
MX2019008170A (es) 2017-01-09 2020-02-07 Ardelyx Inc Compuestos útiles para tratar transtornos del tracto gastrointestinal.
CA3049922A1 (en) 2017-02-10 2018-08-16 Novadaq Technologies ULC Open-field handheld fluorescence imaging systems and methods
US20230124548A1 (en) * 2019-08-23 2023-04-20 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Therapeutic Methods And Uses Thereof
WO2021202286A1 (en) * 2020-03-30 2021-10-07 Dignify Therapeutics, Llc Compositions and methods for treating autonomic dysreflexia

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4481139A (en) * 1983-04-13 1984-11-06 Board Of Regents, The University Of Texas System Peptide antagonists of substance P
US4985896A (en) * 1985-03-29 1991-01-15 Canon Kabushiki Kaisha Laser driving device
US4981744A (en) * 1990-04-24 1991-01-01 Swank Michael W Non-planar expandable honeycomb structure
JP3507494B2 (ja) * 1992-08-13 2004-03-15 ワーナー−ランバート・コンパニー タキキニン拮抗薬
US5610165A (en) * 1994-02-17 1997-03-11 Merck & Co., Inc. N-acylpiperidine tachykinin antagonists
US5744482A (en) * 1994-10-05 1998-04-28 Eli Lilly And Company Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine
US5998444A (en) * 1995-10-24 1999-12-07 Zeneca Ltd. Piperidinyl compounds as NK1 or NK2 antagonists
IL116249A (en) * 1994-12-12 2003-07-06 Pfizer Nk-1 receptor antagonists for the treatment of neuronal damage and stroke
WO1996024353A1 (en) * 1995-02-10 1996-08-15 Eli Lilly And Company Methods of treating or preventing psychiatric disorders
US5795894A (en) * 1995-05-02 1998-08-18 Schering Corporation Piperazino derivatives as neurokinn antagonists
US5990125A (en) 1996-01-19 1999-11-23 Pfizer Inc. NK-1 receptor antagonists for the treatment of cancer
AU5265596A (en) * 1996-04-12 1997-11-07 Neotech Medical Innovations, Inc. Composition and method for the treatment of premenstrual syndrome
US5977104A (en) * 1996-12-02 1999-11-02 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating bipolar disorders
CA2298979A1 (en) * 1997-08-28 1999-03-04 Merck & Co., Inc. Method for treating premenstrual or late luteal phase syndrome
GB9812662D0 (en) * 1998-06-11 1998-08-12 Merck Sharp & Dohme Therapeutic use
KR100514236B1 (ko) 1999-02-24 2005-09-13 에프. 호프만-라 로슈 아게 페닐 유도체 및 피리디닐 유도체
YU59901A (sh) 1999-02-24 2005-07-19 F. Hoffmann-La Roche Ag. Derivati 3-fenilpiridina i njihova primena kao antagonista nk-1 receptora
EP1035115B1 (en) * 1999-02-24 2004-09-29 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
US6291465B1 (en) 1999-03-09 2001-09-18 Hoffmann-La Roche Inc. Biphenyl derivatives
US6274588B1 (en) 1999-05-31 2001-08-14 Hoffmann-La Roche Inc. 4-phenyl-pyrimidine derivatives
JO2308B1 (en) 1999-05-31 2005-09-12 اف. هوفمان- لاروش أيه جي‏ Derivatives of phenylpyrmidine
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
US6479433B1 (en) * 2000-10-02 2002-11-12 Smithers-Oasis Company Polyurethane foam composites for grower applications and related methods

Similar Documents

Publication Publication Date Title
JP2003520232A5 (US07794700-20100914-C00152.png)
JP2003503454A5 (US07794700-20100914-C00152.png)
JP2006503588A5 (US07794700-20100914-C00152.png)
JP2004525194A5 (US07794700-20100914-C00152.png)
JP2005532372A5 (US07794700-20100914-C00152.png)
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
JP2004532810A5 (US07794700-20100914-C00152.png)
JP2004529078A5 (US07794700-20100914-C00152.png)
JP2004515500A5 (US07794700-20100914-C00152.png)
NO20064186L (no) Substituerte pyrazolin sammensetninger for a redusere triglycerider i blod
JP2002506648A5 (US07794700-20100914-C00152.png)
JP2006507281A5 (US07794700-20100914-C00152.png)
JP2003526626A5 (US07794700-20100914-C00152.png)
NO20034863L (no) Deutererte 3-piperidinopropiofenon så vel som legemidler som inneholder disse forbindelser
JP2004002446A5 (US07794700-20100914-C00152.png)
DE60205888D1 (de) Das citrat-salz des 5,8,14,-triazatetracyclo(10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaens
JP2006506499A5 (US07794700-20100914-C00152.png)
CA2489140A1 (en) Dosage form containing pantoprazole as active ingredient
WO2004098577A3 (en) Dosage form containing (s)-pantoprazole as active ingredient
JP2002509169A5 (US07794700-20100914-C00152.png)
JP2003523397A5 (US07794700-20100914-C00152.png)
JP2001294524A5 (US07794700-20100914-C00152.png)
JP2003119141A5 (US07794700-20100914-C00152.png)
JP2003516751A5 (US07794700-20100914-C00152.png)
JP2003501387A5 (US07794700-20100914-C00152.png)